FY2025 Earnings Forecast for Zoetis Issued By Zacks Research

Zoetis Inc. (NYSE:ZTS) – Research analysts at Zacks Research lowered their FY2025 earnings estimates for shares of Zoetis in a report released on Wednesday, January 8th. Zacks Research analyst E. Bagri now forecasts that the company will post earnings per share of $6.36 for the year, down from their prior estimate of $6.37. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Zacks Research also issued estimates for Zoetis’ Q4 2025 earnings at $1.59 EPS, Q4 2026 earnings at $1.79 EPS and FY2026 earnings at $6.97 EPS.

Other equities research analysts have also issued reports about the company. JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners assumed coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Finally, Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus target price of $211.89.

Zoetis Trading Up 0.9 %

NYSE ZTS opened at $164.93 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis has a 12 month low of $144.80 and a 12 month high of $200.53. The company’s fifty day moving average price is $172.08 and its two-hundred day moving average price is $180.20. The company has a market capitalization of $74.41 billion, a price-to-earnings ratio of 31.00, a price-to-earnings-growth ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the previous year, the company posted $1.36 earnings per share. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This is a boost from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.21%. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Hedge Funds Weigh In On Zoetis

Several institutional investors have recently modified their holdings of ZTS. Darwin Wealth Management LLC acquired a new stake in Zoetis in the 3rd quarter valued at approximately $31,000. First Personal Financial Services acquired a new stake in Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP bought a new position in shares of Zoetis in the 3rd quarter valued at about $33,000. Dunhill Financial LLC increased its stake in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Quarry LP raised its holdings in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.